PURPOSE: The US Food and Drug Administration approved abemaciclib in combination with endocrine therapy (ET) for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer (EBC) at high risk of recurrence and a Ki-67 score ≥ 20%. PATIENTS AND METHODS: The approval was based on monarchE, a phase III, open-label, 2-cohort, multicenter trial of patients with EBC randomly assigned to receive abemaciclib plus ET (n = 2,808) or ET alone (n = 2,829). Abemaciclib was given at 150 mg orally twice daily for 2 years. RESULTS: Invasive disease-free survival (IDFS) in the intent-to-treat population was statistically significant at the second IDFS interim analysis (IA; March 2020; hazard ratio [HR; 95% CI], 0.747 [0.598 to 0.932]; P = .0096); however, only 12.5% of patients had completed adjuvant therapy, and the HR for overall survival (OS) was > 1. A prespecified, controlled analysis of IDFS in patients with Ki-67 ≥ 20% in cohort 1 was statistically significant at the final IDFS analysis (July 2020; HR [95% CI], 0.643 [0.475 to 0.872]; P = .0042). At the first OS IA (April 2021), the majority of patients had completed adjuvant therapy, IDFS remained consistent, and potential detriment in OS was not observed for this subgroup (HR [95% CI], 0.767 [0.511 to 1.152]). The HR for OS in the intent-to-treat population at OS IA remained > 1 (HR [95% CI], 1.091 [0.818 to 1.455]). More patients in the abemaciclib plus ET arm experienced treatment emergent adverse events (all grades 98.4% v 88.8%, grade 3 ≥ 49.7% v 16.3%). CONCLUSION: The approval of abemaciclib in adjuvant EBC was limited to patients with high risk of recurrence and Ki-67 ≥ 20%, given their favorable benefit:risk with a statistically significant IDFS advantage and no observed detriment on survival.
PURPOSE: The US Food and Drug Administration approved abemaciclib in combination with endocrine therapy (ET) for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer (EBC) at high risk of recurrence and a Ki-67 score ≥ 20%. PATIENTS AND METHODS: The approval was based on monarchE, a phase III, open-label, 2-cohort, multicenter trial of patients with EBC randomly assigned to receive abemaciclib plus ET (n = 2,808) or ET alone (n = 2,829). Abemaciclib was given at 150 mg orally twice daily for 2 years. RESULTS: Invasive disease-free survival (IDFS) in the intent-to-treat population was statistically significant at the second IDFS interim analysis (IA; March 2020; hazard ratio [HR; 95% CI], 0.747 [0.598 to 0.932]; P = .0096); however, only 12.5% of patients had completed adjuvant therapy, and the HR for overall survival (OS) was > 1. A prespecified, controlled analysis of IDFS in patients with Ki-67 ≥ 20% in cohort 1 was statistically significant at the final IDFS analysis (July 2020; HR [95% CI], 0.643 [0.475 to 0.872]; P = .0042). At the first OS IA (April 2021), the majority of patients had completed adjuvant therapy, IDFS remained consistent, and potential detriment in OS was not observed for this subgroup (HR [95% CI], 0.767 [0.511 to 1.152]). The HR for OS in the intent-to-treat population at OS IA remained > 1 (HR [95% CI], 1.091 [0.818 to 1.455]). More patients in the abemaciclib plus ET arm experienced treatment emergent adverse events (all grades 98.4% v 88.8%, grade 3 ≥ 49.7% v 16.3%). CONCLUSION: The approval of abemaciclib in adjuvant EBC was limited to patients with high risk of recurrence and Ki-67 ≥ 20%, given their favorable benefit:risk with a statistically significant IDFS advantage and no observed detriment on survival.
Authors: A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn Journal: Ann Oncol Date: 2015-05-04 Impact factor: 32.976
Authors: Lynn J Howie; Nancy S Scher; Laleh Amiri-Kordestani; Lijun Zhang; Bellinda L King-Kallimanis; Yasmin Choudhry; Jason Schroeder; Kirsten B Goldberg; Paul G Kluetz; Amna Ibrahim; Rajeshwari Sridhara; Gideon M Blumenthal; Richard Pazdur; Julia A Beaver Journal: Clin Cancer Res Date: 2018-12-14 Impact factor: 12.531
Authors: Harpreet Singh; Amanda J Walker; Laleh Amiri-Kordestani; Joyce Cheng; Shenghui Tang; Pamela Balcazar; Kimberly Barnett-Ringgold; Todd R Palmby; Xianhua Cao; Nan Zheng; Qi Liu; Jingyu Yu; William F Pierce; Selena R Daniels; Rajeshwari Sridhara; Amna Ibrahim; Paul G Kluetz; Gideon M Blumenthal; Julia A Beaver; Richard Pazdur Journal: Clin Cancer Res Date: 2018-03-09 Impact factor: 12.531
Authors: Peter A Fasching; Paul Gass; Lothar Häberle; Bernhard Volz; Alexander Hein; Carolin C Hack; Michael P Lux; Sebastian M Jud; Arndt Hartmann; Matthias W Beckmann; Dennis J Slamon; Ramona Erber Journal: Breast Cancer Res Treat Date: 2019-03-13 Impact factor: 4.872
Authors: N Harbeck; P Rastogi; M Martin; S M Tolaney; Z M Shao; P A Fasching; C S Huang; G G Jaliffe; A Tryakin; M P Goetz; H S Rugo; E Senkus; L Testa; M Andersson; K Tamura; L Del Mastro; G G Steger; H Kreipe; R Hegg; J Sohn; V Guarneri; J Cortés; E Hamilton; V André; R Wei; S Barriga; S Sherwood; T Forrester; M Munoz; A Shahir; B San Antonio; S C Nabinger; M Toi; S R D Johnston; J O'Shaughnessy Journal: Ann Oncol Date: 2021-10-14 Impact factor: 32.976
Authors: Shaily Arora; Preeti Narayan; Christy L Osgood; Suparna Wedam; Tatiana M Prowell; Jennifer J Gao; Mirat Shah; Danielle Krol; Sakar Wahby; Melanie Royce; Soma Ghosh; Reena Philip; Gwynn Ison; Tara Berman; Christina Brus; Erik W Bloomquist; Mallorie H Fiero; Shenghui Tang; Richard Pazdur; Amna Ibrahim; Laleh Amiri-Kordestani; Julia A Beaver Journal: Clin Cancer Res Date: 2022-03-15 Impact factor: 13.801
Authors: Giuseppe Viale; Anita Giobbie-Hurder; Meredith M Regan; Alan S Coates; Mauro G Mastropasqua; Patrizia Dell'Orto; Eugenio Maiorano; Gaëtan MacGrogan; Stephen G Braye; Christian Ohlschlegel; Patrick Neven; Zsolt Orosz; Wojciech P Olszewski; Fiona Knox; Beat Thürlimann; Karen N Price; Monica Castiglione-Gertsch; Richard D Gelber; Barry A Gusterson; Aron Goldhirsch Journal: J Clin Oncol Date: 2008-11-03 Impact factor: 44.544
Authors: J H Todd; C Dowle; M R Williams; C W Elston; I O Ellis; C P Hinton; R W Blamey; J L Haybittle Journal: Br J Cancer Date: 1987-10 Impact factor: 7.640
Authors: Stephen R D Johnston; Nadia Harbeck; Roberto Hegg; Masakazu Toi; Miguel Martin; Zhi Min Shao; Qing Yuan Zhang; Jorge Luis Martinez Rodriguez; Mario Campone; Erika Hamilton; Joohyuk Sohn; Valentina Guarneri; Morihito Okada; Frances Boyle; Patrick Neven; Javier Cortés; Jens Huober; Andrew Wardley; Sara M Tolaney; Irfan Cicin; Ian C Smith; Martin Frenzel; Desirée Headley; Ran Wei; Belen San Antonio; Maarten Hulstijn; Joanne Cox; Joyce O'Shaughnessy; Priya Rastogi Journal: J Clin Oncol Date: 2020-09-20 Impact factor: 50.717
Authors: Elisabeth K Trapp; Peter A Fasching; Tanja Fehm; Andreas Schneeweiss; Volkmar Mueller; Nadia Harbeck; Ralf Lorenz; Claudia Schumacher; Georg Heinrich; Fabienne Schochter; Amelie de Gregorio; Marie Tzschaschel; Brigitte Rack; Wolfgang Janni; Thomas W P Friedl Journal: Cancers (Basel) Date: 2022-08-16 Impact factor: 6.575